Highlights scPharmaceuticals Inc.

Equities

SCPH

US8106481059

Real-time Estimate Cboe BZX Other stock markets 01:23:57 2024-04-29 pm EDT			5-day change	1st Jan Change
4.545 ^USD	+1.22%		+0.88%	-26.48%

Apr. 24	ScPharmaceuticals Inc. Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) Injection	CI
Mar. 13	Transcript : ScPharmaceuticals Inc., Q4 2023 Earnings Call, Mar 13, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ScPharmaceuticals Inc. Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of Furoscix Auto-Injector (Furosemide 80Mg/Ml) Injection	Apr. 24	CI
ScPharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
ScPharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
ScPharmaceuticals Expects Higher Q4 Product Sales	Jan. 04	MT
ScPharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2023	Jan. 04	CI
ScPharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Scpharmaceuticals Announces Positive Feedback from Two Fda Meetings on Key Long-Term Growth Initiatives	23-09-19	CI
ScPharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
ScPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion	23-08-01	CI
ScPharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
SCPHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-22	AQ
ScPharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-22	CI
ScPharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-22	CI
ScPharmaceuticals Inc. Announces Launch and Commercial Availability of FUROSCIX® (Furosemide Injection)	23-02-21	CI
ScPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update	23-01-30	CI
ScPharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
ScPharmaceuticals Inc. Revises Earnings Guidance for the Year 2022	22-11-09	CI
Top Midday Decliners	22-10-10	MT
U.S. FDA approves ScPharmaceuticals' heart failure therapy	22-10-10	RE
U.S. FDA approves ScPharmaceuticals' heart failure therapy	22-10-10	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights scPharmaceuticals Inc.

Equities

SCPH

US8106481059

Highlights

Filters